%0 Journal Article
%T Ki-67 biomarker in breast cancer of Indian women
%A Amit V. Patil
%A Rajeev Singhai
%A Rahul S. Bhamre
%A Vinayak W. Patil
%J North American Journal of Medical Sciences
%D 2011
%I North American Journal of Medical Sciences
%X Background: Biological markers that reliably predict clinical or pathological response to primary systemic therapy early during a course of chemotherapy may have considerable clinical potential. Aims: Aims of study to evaluated changes in Ki-67 (MIB-1) labeling index and apoptotic index (AI) before, during, and after neoadjuvant anthracycline chemotherapy in breast cancer in Indian women. Materials and Methods: Breast cancer tissues were collected from Grant Medical College and Sir J.J. Group of Hospitals, Mumbai, India. Twenty-seven patients receiving neoadjuvant FEC (5-fluorouracil, epirubicin, and cyclophosphamide) chemotherapy for operable breast cancer underwent repeat core biopsy after 21 days of treatment. Results: The objective clinical response rate was 56%. Eight patients (31%) achieved a pathological response by histopathological criteria; two patients had a near-complete pathological response. Increased day-21 AI was a statistically significant predictor of pathological response (p = 0.049). A strong trend for predicting pathological response was seen with higher Ki-67 indices at day 21 and AI at surgery (p = 0.06 and 0.06, respectively). Conclusion: The clinical utility of early changes in biological marker expression during chemotherapy remains unclear. Until further prospectively validated evidence confirming the reliability of predictive biomarkers is available, clinical decision-making should not be based upon individual biological tumor biomarker profiles.
%K Ki-67 (MIB-1)
%K breast cancer
%K prognostic factor
%K proliferative labeling index
%K apoptotic index
%K chemotherapy
%K primary systemic therapy.
%U http://najms.org/resources/PDF+119-128++Ki-67+biomarker+in+breast+cancer+of+Indian+women.pdf